Objectives: To assess risk of a first clinical diagnosis of CNS demyelination (FCD) in relation to measures of Epstein-Barr virus (EBV) infection within the context of other known risk factors.
EBV infection of autoreactive B cells, 7 or defective CD8ϩ T-cell control of EBV-infected B lymphocytes. 8 Elevated levels of EBV DNA in the peripheral blood, close to the time of diagnosis, might be expected but have been inconsistently observed. 9 -11 Previously described genetic 12 and environmental [13] [14] [15] risk factors for MS may operate, at least in part, by influencing the host response to infections such as EBV. Finally, the commonly observed latitudinal gradient in MS may be the result of variation in EBV infection, 5 but this has not yet been formally assessed in individual level studies.
Here we examine EBV DNA load, EBVspecific antibody (immunoglobulin G [IgG]) titers, and history of IM in a large populationbased study in relation to onset of CNS demyelination. We also examine the interplay (confounding or interaction) between these markers of EBV infection and genetic and environmental factors implicated in MS risk.
METHODS The Ausimmune Study is described in detail elsewhere. 16 Briefly, this was a multicenter case-control study, recruiting individuals (aged 18 -59 years) in 4 regions in eastern Australia. Cases had an incident first clinical diagnosis of CNS demyelination (FCD), including those presenting with a classic first demyelinating event (FDE, n ϭ 216), a first diagnosis of primary progressive MS (PPMS, n ϭ 18) and those in whom, in retrospect, there had been a previous, undiagnosed, probable FDE (n ϭ 48). Controls were matched to cases (2:1) on age (within 2 years), sex, and study region. We collected self-report data on history of IM ("have you ever had glandular fever?") and age at infection, smoking, exposure to infant siblings, and sun exposure over the lifetime. Silicone skin casts were used to objectively measure cumulative past sun exposure, 17 vitamin D status was assessed as the serum 25-hydroxyvitamin D [25(OH)D] concentration, 13 and DNA was genotyped for a range of MSrelated genes, using proxy single nucleotide polymorphisms (SNPs). 12, 18 In a nested EBV study (n ϭ 215 cases, n ϭ 216 controls), we measured whole blood quantitative EBV DNA load using 3 separate primers targeting EBNA-1, BHRF-1, and BWRF-1 gene regions, in 2 different laboratories. EBV DNA load quantification using the first 2 primers is described elsewhere. 19 For the BWRF-1 gene region, DNA was extracted from EDTA whole blood using the Qiagen Blood mini kit (Qiagen, Hilden, Germany). One microgram of DNA was subjected to real-time quantitative PCR as previously described. 20 The Namalwa cell line (containing 2 EBV copies/cell) was used in the standard curve to determine copy numbers 21 (expressed as EBV copies/g of DNA). Quantification was performed on EDTA whole blood rather than peripheral blood mononuclear cells (PBMC) to capture EBV sourced from plasma (representing active virus production) as well as PBMCs (representing latent infection). Quantitative IgG antibody titers to EBV viral capsid antigen (VCA) were measured by automated enzyme immunoassay (Star Corp, Stillwater, MN) 22 and antibodies to EBNA complex and early antigen (diffuse and restricted, EA-D and EA-R, respectively) by immunofluorescence assay. 23 SNP genotyping was performed using the SNPline method (KBiosciences, Hoddesdon Herts, UK).
Statistical analysis.
Of 311 eligible cases, 282 (91%) agreed to participate. Of 1,118 controls initially selected, 937 were successfully contacted (84%) and 558 participated in the study (60% of those contacted). Results here are based on 276 cases and 543 matched controls (see table e-1 on the Neurology ® Web site at www.neurology.org) with data on history of IM, including those in the EBV nested study (FCD cases, n ϭ 215, matched controls, n ϭ 216; serology unavailable for 9 cases).
EBV DNA load was highly skewed, with no detectable EBV DNA in nearly 50% of samples. We thus examined this factor as both a dichotomous (present/absent) and a continuous variable. EBV-specific antibody titers were positively skewed and were transformed to an approximately normal distribution using the base 2 logarithm of the reciprocal of the dilution of the titers as a continuous variable. 3 In the log base 2 transformation, the regression coefficient estimates the logarithm of the odds ratio (OR) associated with a 2-fold difference. We used Spearman correlation to examine the correlation between different measures of EBV infection and logistic regression (IM as outcome), general linear models (antibody titers), and nonparametric tests (EBV DNA load) to examine associations between these measures and other factors, e.g., age and sex. Conditional logistic regression was used to examine FCD risk in relation to markers of EBV infection, testing other known MS risk factors as confounders or effect modifiers, the latter by adding the relevant product term to the model and assessing the resultant reduction in deviance using the likelihood ratio test. 24 We also estimated the additive effect of having multiple risk factors. Adjusted ORs (AOR), including adjustment for educational level, smoking, and vitamin D status, and 95% confidence intervals (95% CI), are presented. All analyses were undertaken using Stata (version 9.2; StataCorp LP, College Station, TX). Participants with missing data on factors of interest were excluded from those specific analyses.
Standard protocol approvals, registrations, and patient consents. The Ausimmune Study was approved by 9 regional Human Research Ethics Committees. All participants gave written informed consent.
RESULTS EBV infection measures among control
participants. EBV DNA load measured using the BWRF-1 gene region (but not EBNA-1 or BHRF-1) was correlated with anti-VCA and anti-EA-R IgG titers (anti-VCA r ϭ 0.24, p Ͻ 0.001; anti-EA-R r ϭ 0.24, p Ͻ 0.001) but not anti-EBNA (r ϭ 0.08, p ϭ 0.25) or anti-EA-D (r ϭ 0.08, p ϭ 0.25) titers.
A positive history of IM was associated with higher anti-EBV-specific IgG titers (log 2): anti-EBNA, OR ϭ 1.12 (95% CI 0.93 to 1.35); anti-VCA, OR ϭ 1.23 (95% CI 0.98 to 1.56); anti-EA-D, OR ϭ 1.18 (95% CI 0.97 to 1.44); anti-EA-R, OR ϭ 1.14 (95% CI 0.94 to 1.37). The highest mean anti-EBNA titers were for those reporting IM at 6 -10 years of age, but the difference was statistically significant only in comparison to the 11-15 years age group (p ϭ 0.02). EBV DNA load was not associated with history of IM for any of the 3 gene regions examined. Table 1 shows variation in the markers of EBV infection among controls. Additionally, EBV DNA load and anti-EBV specific IgG titers did not differ significantly by current or early childhood (0 to 5 years) latitude of residence, and there was no difference in EBV-specific IgG titers between Australianborn and overseas-born participants or according to age at immigration (data not shown). However, median EBV DNA load was higher in overseas-born controls than Australian-born (median [interquartile range (IQR)]: 0.25 [0 -1.1]; 0 [0 -0.65], respectively, p ϭ 0.05), with the greatest difference for those arriving in Australia as adults. Adjustment for sex and current age did not alter these findings.
Markers of EBV infection and FCD risk. Current EBV
DNA load. The proportion with detectable EBV DNA was not significantly different for cases compared to matched controls (table 2, results shown only for the BWRF-1 gene region) and there was no increased Table 1 EBV DNA load, EBV-specific antibodies, and history of IM in controls in the Ausimmune Study (table 3) . There was no multiplicative interaction between 25(OH)D concentration and anti-EBNA IgG titer on FCD risk ( p ϭ 0.41).
Among controls, there was no association between leisure-time sun exposure for 5-year age brackets from 6 to 25 years and history of IM (excluding from successive analyses those who had had IM at an earlier age). In case-control analyses, sun exposure and EBV infection measures were independently associated with FCD risk with no evidence of interaction (e.g., difference in effect of anti-EBNA titers on FCD risk by leisure-time sun exposure, p ϭ 0.31). The findings obtained substituting in the silicone cast score as the sun exposure measure gave similar results.
A greater number of days of exposure to infant siblings was associated with a nonsignificant reduced FCD risk (AOR ϭ 0.87 [95% CI 0.68 to 1.12]) per Table 3 Modification Here there was no significant multiplicative interaction (p ϭ 0.50), but a marked increase in risk when both factors were present (figure).
of the association between EBV DNA load (BWRF-1) and FCD risk (AOR, 95% CI) by serum 25(OH)D concentration
There was increased FCD risk in association with the G allele of a SNP in the HLA-A region (rs6904029) (OR ϭ 3.62 [95% CI 1.69 to 7.78]) and a marked increase in FCD risk with increasing anti-EBNA titer in association with this allele ( figure) .
Although there was no association between SNPs in the CTLA-4 gene and FCD risk in crude analyses (e.g., rs11571316: OR ϭ 0.86 [95% CI 0.60 to 1.21]), this SNP was an effect modifier for the association between anti-EBNA titer and FCD risk ( p[interaction] ϭ 0.04). Here the adverse effect of high anti-EBNA titer (Ͼ320) was more marked in the absence, compared to the presence, of the A-allele (table 4). The odds of being a FCD case were markedly reduced when the anti-EBNA titer was low and the A allele was present.
Latitudinal variation in EBV infection and the latitudi-
nal FCD incidence gradient. Among controls, EBV DNA load did not vary by latitude for any of the 3 gene regions examined and there was no association between latitude and anti-EBNA, anti-EA-D, or anti-EA-R IgG titers. After adjustment for age and sex, anti-VCA IgG titers tended to decrease with increasing latitude (␤ ϭ Ϫ0.04 [95% CI Ϫ0.08 to 0.004], p ϭ 0.08 change in anti-VCA [log2] titer per higher degree of latitude). The odds of a positive history of IM also decreased with increasing latitude (OR ϭ 0.96 [95% CI 0.92 to 1.00]), with the magnitude of the estimate unaffected by adjustment for age, sex, educational level, or number of years smoking. This represents a 35% decrease in the odds for IM from the lowest latitude to the highest latitude region. There was no latitudinal variation in the age of reporting IM ( p ϭ 0.44) or in the associations between markers of EBV infection and FCD risk.
Figure
Increasing risk of first clinical diagnosis of CNS demyelination associated with increasing anti-Epstein-Barr virus nuclear antigen (EBNA) titer and presence of DR15 or HLA-A susceptibility genotype (adjusted odds ratios, adjusting for total years smoked, vitamin D status, and educational category) DISCUSSION No significant difference was observed in the whole blood EBV DNA load of cases with a first clinical diagnosis of CNS demyelination compared to control participants. In contrast, FCD cases were more likely than age-and sex-matched controls to report a history of IM and had higher anti-EBNA IgG titers, possibly reflecting not just past EBV infection, but impaired immune control of that infection. Of interest, the host constitution in relation to 3 gene variants, HLA-DR15, HLA-A, and CTLA4, altered the association between higher anti EBNA IgG titers and FCD risk. Neither EBV DNA load nor markers of past EBV infection accounted for the latitudinal gradient in FCD incidence previously observed in the Ausimmune Study. 25 Strengths of this multicenter study include recruitment of incident cases from study regions spanning a wide latitude range, the examination of a broad spectrum of environmental factors, and the measurement of quantitative EBV DNA load and titers for 4 EBV-specific antibodies. The focus was on early disease, with similar findings for the full FCD group, the classic FDE group, the FDE group with interview closest to the first event, and for those who had, and had not, received methylprednisolone treatment. One limitation was that data on EBV-specific antibodies and EBV DNA load were available for only a subset of participants, so that some analyses are limited by sample size. The EBV DNA load assay was sensitive and showed an expected correlation with antibodies produced relatively early in the host response to EBV infection. 26 Nevertheless, undertaking measurements on whole blood does not permit evaluation of the relative contribution of EBV load in plasma (related to reactivation and virus production) compared to PBMCs (a marker of latent infection load).
Late infection with EBV (manifested as IM) could itself directly increase MS risk or be a marker of more hygienic conditions in early life. The hygiene hypothesis posits that lower infection exposure in early life results in a less targeted immune response to common infections, a generally more inflammatory immune milieu, and an increased risk of autoimmune diseases. 27 Here, however, we found no evidence that the association between FCD and IM was altered by the reported age of IM. Higher infant sibling exposure was not associated with lower anti-EBNA IgG titer and did not modify the association between EBV indices and FCD risk.
Our findings are also not consistent with a strong role for acute EBV infection/reactivation being the trigger of the immediate demyelinating event. Even in FDE cases where the time from first event to blood collection was short (Ͻ3 months), we found no significant increase in EBV DNA load, as has been reported for some other Th-1 autoimmune diseases. 28, 29 Further, FCD risk associated with the host antibody response to acute infection/reactivation (anti-VCA and anti-EA-D IgG) did not persist after adjustment for anti-EBNA antibodies, and the latter appeared to be the most important serologic index.
Although several commentators have hypothesized that MS is caused by an interaction whereby low vitamin D status heightens the risk of EBV infection and subsequent autoimmune responses, 30 we found no evidence of any interaction between either sun exposure or vitamin D status and history of IM or higher anti-EBNA titers. These factors appeared to be independent risk factors for onset of CNS demyelination in this study.
Higher 25(OH)D concentrations were associated with lower EBV DNA load in controls-this is consistent with the posited beneficial effect of vitamin D on viral and intracellular infections. 31, 32 However, the combination of having higher 25(OH)D concentrations and higher levels of EBV DNA in blood was associated with increased FCD risk. One explanation is that an unmeasured factor that allows reactivation of EBV even in a high vitamin D environment, e.g., defective CD8ϩ T cell function, is, in itself, a FCD disease determinant. Further studies are needed to confirm and further explore this result.
Human leukocyte antigen (HLA) class I molecules complex with viral peptides on virus-infected cells to allow recognition by CD8ϩ T cells responsible for controlling EBV infection. Thus, the observed interaction between markers of EBV infection and SNPs in the HLA class I region is plausible. A previous study has shown an increased frequency of CD8ϩ T cells recognizing EBV-derived peptides in association with HLA-A2 and B7 alleles in MS cases but not controls, 33 although this was not confirmed in another study. 34 As has been previously reported, 35 ,36 it appears to be particularly adverse for people who are genetically susceptible (HLA-DR15ϩ) to have higher levels of anti-EBNA IgG. We have additionally shown that the presence/absence of the A allele of a SNP in the CTLA4 gene modifies the association between anti-EBNA titer and FCD risk. This has not been previously described in MS, but has been observed in systemic lupus erythematosus, 37 another EBV-associated autoimmune disease. These findings from this large, population-based study of first onset of CNS demyelination are consistent with other studies showing an association between markers of past EBV infection and MS risk. They do not provide strong support that whole blood EBV DNA load is of major importance at the onset of clinical disease, and we found no interaction with other risk factors including smoking, vitamin D status, or past sun exposure. We have confirmed previous findings of an additive interaction between HLA class II and EBV-specific antibody levels, and have additionally shown further interactions between SNPs in the HLA class I region and CTLA-4.
